Your Health, We Care
Revumenib is a menin inhibitor indicated for the following conditions:
Treatment of relapsed or refractory acute leukemia in adult and pediatric patients aged 1 year and older, with confirmed lysine methyltransferase 2A (KMT2A) translocation detected by an FDA-authorized test.
Treatment of relapsed or refractory acute myeloid leukemia in adult and pediatric patients aged 1 year and older, with susceptible nucleophosmin 1 (NPM1) mutation and in the absence of other satisfactory alternative treatment options.
FDA，2025.10
It is indicated for the treatment of relapsed or refractory acute leukemia (with···【more】
Release date：2026-01-05Recommended：10
